Ra Pharmaceuticals -2.1% as it plans $50M offering

Ra Pharmaceuticals (NASDAQ:RARX) is 2.1% lower postmarket after word that it"s pursuing a $50M stock offering.

Net proceeds will go to fund its phase 2 trial for RA101495 for gMG, among other pipeline programs and general purposes.

Underwriters are expected to get a 30-day option to buy up to $7.5M in additional shares.

Joint book-runners are Credit Suisse, Jefferies, and BMO Capital Markets.

Nguồn: seekingalpha.com